Keebeck Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,763
Closed -$338K – 481
2026
Q2
$338K Sell
10,763
-14,413
-57% -$425K 0.03% 345
2026
Q1
$623K Buy
25,176
+2,149
+9% +$51.2K 0.07% 204
2025
Q4
$537K Buy
23,027
+5,245
+29% +$117K 0.06% 207
2025
Q3
$350K Sell
17,782
-2,645
-13% -$54.4K 0.04% 277
2025
Q2
$443K Buy
20,427
+11,127
+120% +$263K 0.06% 220
2025
Q1
$226K Buy
+9,300
New +$209K 0.03% 253

Other funds holding CPRX

Keebeck Wealth Management's CPRX Position: Q3 2026 in Review

Keebeck Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 10,763 shares — an estimated $338K sold.

Keebeck Wealth Management first reported a position in CPRX in Q1 2025 and held it in 6 quarters. The position peaked at $623K in Q1 2026. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Keebeck Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Keebeck Wealth Management sold 10,763 Catalyst Pharmaceutical shares in Q3 2026, an estimated $338K.
  • Keebeck Wealth Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 6 quarters.
  • Keebeck Wealth Management's Catalyst Pharmaceutical position peaked at $623K in Q1 2026.
  • 3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Keebeck Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.